Next-Generation Bispecific Nanobody Immunocytokine Targeting PDCD1 and CD8 for Autoimmune Disease Therapy

VHH-P293 is a humanized nanobody-based biologic currently in the Biological Testing development stage. This innovative candidate targets programmed cell death 1 (PDCD1) and T-cell surface glycoprotein CD8, two pivotal immune regulatory molecules. By engaging both targets, VHH-P293 offers a promising strategy for the therapeutic modulation of immune responses implicated in autoimmune disease. Engineered as a sophisticated heterodimeric immunocytokine fusion construct, VHH-P293 has the potential to transform autoimmune disease treatment through targeted immune intervention while minimizing systemic toxicity.

Licensing Opportunity

VHH-P293 is available for licensing and partnership opportunities. We invite collaborations from industry and academic partners interested in advancing innovative nanobody-based therapeutics for autoimmune disease.

Development Phase

Modality

VHH-P293 is a heterodimeric, bispecific immunocytokine, carefully engineered from two polypeptide chains. Each chain utilizes a single-domain, humanized nanobody format, offering enhanced tissue penetration and robust stability due to the small molecular size and simple structure. The design incorporates a human IgG1 Fc domain with an N297G mutation, providing an optimized pharmacokinetic profile while reducing effector functions. Site-specific fusion of human interleukin-2 further enables localized immune modulation. The precise architecture grants VHH-P293 the ability to effectively engage targets within immune cell populations, delivering potential for improved efficacy and lower immunogenicity in autoimmune disease treatment.

Target

PDCD1 and CD8 are critical modulators of cellular immunity. PDCD1, an immune checkpoint receptor, is predominantly expressed on activated T-cells and plays a fundamental role in modulating T-cell activity and maintaining peripheral tolerance. CD8 is a glycoprotein expressed mainly on cytotoxic T lymphocytes, facilitating antigen recognition and direct immune response. In autoimmune disease, abnormal regulation or signaling through PDCD1 and CD8 pathways contributes to immune system overactivity and tissue damage. Simultaneous targeting of PDCD1 and CD8 with VHH-P293 can help restore immune balance, limit autoimmunity, and address underlying immune dysregulation. The dual-target approach enhances the strategic value of VHH-P293 for positioning in the autoimmune disease therapeutics landscape, leveraging PDCD1 and CD8 as tractable, clinically validated immunological nodes.

Mechanism of Action

VHH-P293 exerts its therapeutic action by simultaneously binding to PDCD1 and CD8 on T lymphocytes. By engaging PDCD1, the molecule modulates checkpoint-mediated inhibitory signaling, promoting controlled T-cell activation. Concurrent engagement of CD8 directs the biologic toward cytotoxic T-cell subsets, allowing localized immunomodulation. Incorporation of an interleukin-2 moiety further amplifies immune regulatory effects, harnessing the power of cytokine biology for enhanced efficacy. The nanobody platform structure enables modular adaptability, supporting future applications such as bispecific constructs, antibody-drug conjugates (ADC), and additional immunocytokine formats. This flexible therapeutic mechanism positions VHH-P293 as a leading candidate for innovative immunomodulatory strategies in the autoimmune setting.

Autoimmune Disease

Autoimmune diseases comprise a spectrum of chronic conditions characterized by aberrant immune responses directed against the body's own tissues. These disorders collectively affect millions worldwide, imposing significant personal and socioeconomic burdens. Common examples include rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, each presenting with unique, often progressive clinical manifestations. Standard treatments for autoimmune diseases range from broad immunosuppressants to newer targeted therapies aimed at specific immune pathways. However, limitations such as incomplete responses, increased risk of infections, and adverse systemic effects remain prevalent. There exists a critical need for more selective, effective, and safer therapeutics that can recalibrate the immune response while preserving normal host defenses. By precisely targeting PDCD1 and CD8, VHH-P293 holds promise to address these unmet needs, offering a next-generation approach to restoring immune tolerance without overt immunosuppression.